FHD-909 is under clinical development by Foghorn Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FHD-909’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FHD-909 overview
FH-909 is under development for the treatment of BRG1 mutated cancers such as non-small cell lung cancer. It acts by targeting SMARCA2 (BRM) and is being developed based on Gene Traffic Control platform. It is administered through oral route.
Foghorn Therapeutics overview
Foghorn Therapeutics (Foghorn) is a clinical-stage biotechnology company that focuses on the development of a new class of medicines aimed at treating serious diseases by correcting abnormal gene expression. The company’s primary activities include the modulation of the chromatin regulatory system, which orchestrates gene expression in cells, using their proprietary gene traffic control platform. Foghorn Therapeutics products pipeline includes FHD-286 (BRM / BRG1), FHD-609 (BRD9), Selective BRM, and ARID1B. Its potential therapies are used for treatment spectrum of diseases, including various types of cancer. Foghorn is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of FHD-909’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
